{"analyses":[{"ciLowerLimit":"0.42","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.56","estimateComment":"A hazard ratio \\< 1 favours osimertinib","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.530","paramType":"Hazard Ratio (HR)","paramValue":"0.81","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA - Not calculated as insufficient number of events to enable upper limit of 95% confidence interval to be calculated","groupId":"OG000","lowerLimit":"46.49","upperLimit":"NA","value":"53.95"},{"comment":"NA - Not calculated as insufficient number of events to enable median and upper limit of 95% confidence interval to be calculated","groupId":"OG001","lowerLimit":"42.05","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"Time from the date of randomisation until death by any cause","dispersionType":"95% Confidence Interval","groups":[{"description":"80mg once daily tablet","id":"OG000","title":"Osimertinib"},{"description":"Matching Placebo","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Date of randomisation to date of death by any cause. Assessed up to a maximum of approximately 63 months","title":"Overall Survival (Duration)","type":"SECONDARY","unitOfMeasure":"Months"}